Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251974 · ClinicalTrials.gov registry record
Assay to Measure Beta Blocker Adherence
A clinical trial, sponsored by Summa Health System.
- Terminated
- Registry status
- 27
- Enrollment target
NCT05251974: Clinical Trial study, sponsored by Summa Health System.
NCT05251974 is a clinical trial that was terminated before completion, run by Summa Health System. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05251974 was terminated before completion, sponsored by Summa Health System.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.
Primary Outcome
Requiring readmission or an urgent outpatient visit for heart failure
Interventions
- DIAGNOSTIC_TEST Quest beta blocker assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-11-15 |
Why NCT05251974 stopped before completion
NCT05251974 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Quest beta blocker assay is the first listed.
NCT05251974 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05251974 about?
NCT05251974 is a clinical study titled "Assay to Measure Beta Blocker Adherence". This study will assess the feasibility and efficacy of using serum assay developed by Quest Diagnostics to detect the presence of beta blockers, specifically carvedilol and metoprolol succinate, in patients with heart failure.
What is the current status of trial NCT05251974?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2022-03-02. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT05251974?
The interventions under investigation include: Quest beta blocker assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05251974?
This trial is sponsored by Summa Health System, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI